Potassium-sparing agents during diuretic therapy in hypertension. 1971

T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney

Three pharmacological agents in use as "potassium-sparing" drugs have been tested by serial measurements of total exchangeable potassium (K(E)) during 4 to 12 weeks of oral diuretic therapy in hypertensive subjects. Triamterene seemed ineffective in the dosage used (50 mg twice daily). Spironolactone (25 mg twice daily) reduced K loss to a considerable extent, while Slow-K (32 mEq daily) completely reversed previous K(E) deficits. Plasma K levels were a poor indication of degree of K(E) restoration.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011191 Potassium Deficiency A condition due to decreased dietary intake of potassium, as in starvation or failure to administer in intravenous solutions, or to gastrointestinal loss in diarrhea, chronic laxative abuse, vomiting, gastric suction, or bowel diversion. Severe potassium deficiency may produce muscular weakness and lead to paralysis and respiratory failure. Muscular malfunction may result in hypoventilation, paralytic ileus, hypotension, muscle twitches, tetany, and rhabomyolysis. Nephropathy from potassium deficit impairs the concentrating mechanism, producing POLYURIA and decreased maximal urinary concentrating ability with secondary POLYDIPSIA. (Merck Manual, 16th ed) Deficiencies, Potassium,Deficiency, Potassium,Potassium Deficiencies
D002752 Chlorthalidone A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. Chlorphthalidolone,Phthalamudine,Chlortalidone,Hygroton,Oxodoline,Thalitone
D004232 Diuretics Agents that promote the excretion of urine through their effects on kidney function. Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013148 Spironolactone A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827) Spirolactone,Aldactone,Aldactone A,Aquareduct,Duraspiron,Espironolactona Alter,Espironolactona Mundogen,Flumach,Frumikal,Jenaspiron,Novo-Spiroton,Practon,SC-9420,Spiractin,Spiro L.U.T.,Spiro Von Ct,Spirobeta,Spirogamma,Spirolang,Spirono-Isis,Spironone,Spirospare,Veroshpiron,Verospiron,Verospirone,Ct, Spiro Von,Novo Spiroton,NovoSpiroton,SC 9420,SC9420,Spirono Isis,Von Ct, Spiro

Related Publications

T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
December 1972, Therapeutique (La Semaine des hopitaux),
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
August 1984, Clinical pharmacology and therapeutics,
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
July 1972, Lancet (London, England),
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
December 1981, The Medical letter on drugs and therapeutics,
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
June 1975, Current therapeutic research, clinical and experimental,
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
December 1987, Journal of clinical hypertension,
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
August 1966, The New Zealand medical journal,
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
January 1979, Acta medica Scandinavica,
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
January 1984, Acta pharmacologica et toxicologica,
T J McKenna, and J F Donohoe, and T G Brien, and J J Healy, and B S Canning, and F P Muldowney
May 1988, International journal of clinical pharmacology, therapy, and toxicology,
Copied contents to your clipboard!